- Conditions
- Hidradenitis Suppurativa
- Interventions
- Ertapenem
- Drug
- Lead sponsor
- Henry Ford Health System
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 217–240
of 2,406
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Oral Bacterial Infection, Mechanical Ventilation Complication
- Interventions
- SwishKit + Oral care treatment as usual, Oral care treatment as usual
- Device · Procedure
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Hidradenitis Suppurativa
- Interventions
- Remibrutinib Dose A, Remibrutinib Dose B, Placebo 1, Placebo 2
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 12 Years to 100 Years
- Enrollment
- 565 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Fremont, California + 30 more
- Conditions
- Meningitis, Meningococcal
- Interventions
- MenABCWY vaccine, Placebo, MenACWY vaccine, MenB vaccine
- Combination Product · Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 15 Years to 25 Years
- Enrollment
- 1,250 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 48
- States / cities
- Jonesboro, Arkansas • Banning, California • Chula Vista, California + 42 more
- Conditions
- HIV, Tuberculosis
- Interventions
- lopinavir/ritonavir, rifabutin
- Drug
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2008
- U.S. locations
- 1
- States / cities
- Waukegan, Illinois
- Conditions
- Aspergillosis, Candidiasis, Fungemia, Mycoses
- Interventions
- FK463, Fluconazole
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2000
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Infections, Streptococcal
- Interventions
- Pneumococcal vaccine GSK2189242A, Placebo, Prevnar 13®, PedvaxHIB®
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 6 Weeks to 12 Weeks
- Enrollment
- 1,806 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2016
- U.S. locations
- 5
- States / cities
- Chinle, Arizona • Fort Defiance, Arizona • Whiteriver, Arizona + 2 more
- Conditions
- Skin and Subcutaneous Tissue Bacterial Infections
- Interventions
- Delafloxacin, Linezolid, Vancomycin
- Drug
- Lead sponsor
- Melinta Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 256 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 31
- States / cities
- Mobile, Alabama • Montgomery, Alabama • Buena Park, California + 27 more
- Conditions
- Acute Bacterial Infections, Acute Viral Infections
- Interventions
- Not listed
- Lead sponsor
- The Plasma Source
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Southampton, Pennsylvania
- Conditions
- Clostridium Infections, Diarrhea
- Interventions
- Rifaximin (Xifaxan), Vancomycin
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 237 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 63
- States / cities
- Scottsdale, Arizona • Redlands, California • Longmont, Colorado + 54 more
- Conditions
- Cholera
- Interventions
- Vaxchora
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2025
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Atopic Dermatitis
- Interventions
- Roseomonas mucosa
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 3 Years to 99 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Sexually Transmitted Infections, HIV Infections
- Interventions
- Not listed
- Lead sponsor
- University of Mississippi Medical Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Jackson, Mississippi
- Conditions
- HIV, Tuberculosis
- Interventions
- Bictegravir (BIC), Tenofovir alafenamide (TAF), Long-acting injectable formulation of cabotegravir (CAB LA), Dolutegravir (DTG), Atazanavir/ritonavir (ATV/r), Darunavir/ritonavir (DRV/r), Lopinavir/ritonavir (LPV/r), Cobicistat, Ritonavir, First-Line TB Treatment, Second-Line TB Treatment, Doravirine (DOR)
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- Not listed
- Enrollment
- 205 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 13
- States / cities
- Los Angeles, California • San Diego, California • Aurora, Colorado + 7 more
- Conditions
- Bacterial Pneumonia
- Interventions
- IV meropenem, I.V. Meropenem, Parenteral aminoglycoside; tobramycin for injection USP OR gentamicin sulfate injection solution concentrate 5mg.kg IV q24h; amikacin sulfate injection USP 20 mg/kg IV q24h, Linezolid or Vancomycin (per institutional guidelines) will be available for MRSA coverage., tobramycin nebulization
- Drug · Device
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 8
- States / cities
- San Mateo, California • Gainesville, Florida • Atlanta, Georgia + 5 more
- Conditions
- Onychomycosis
- Interventions
- SUBA-itraconazole, Itraconazole, Placebo
- Drug
- Lead sponsor
- Halcygen Pharmaceuticals Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 8
- States / cities
- Altamonte Springs, Florida • Miami, Florida • Boise, Idaho + 5 more
- Conditions
- Tularaemia
- Interventions
- Placebo, Undiluted Francisella tularensis live attenuated vaccine
- Other · Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 228 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2012
- U.S. locations
- 5
- States / cities
- Decatur, Georgia • Iowa City, Iowa • Baltimore, Maryland + 2 more
- Conditions
- Tuberculosis
- Interventions
- Rifapentine, 25-desacetyl Rifapentine, Isoniazid
- Drug
- Lead sponsor
- Centers for Disease Control and Prevention
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2001
- U.S. locations
- 20
- States / cities
- Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 15 more
- Conditions
- Bacteremia, AmpC Beta-lactamase
- Interventions
- Not listed
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2017
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Post Treatment Lyme Disease Syndrome
- Interventions
- Kundalini Yoga
- Behavioral
- Lead sponsor
- Research Foundation for Mental Hygiene, Inc.
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 2
- States / cities
- Southport, Connecticut • New York, New York
- Conditions
- Diphtheria, Tetanus, Pertussis
- Interventions
- DAPTACEL®: DTaP
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 4 Years to 6 Years
- Enrollment
- 649 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2007
- U.S. locations
- 22
- States / cities
- Fayetteville, Arkansas • Jonesboro, Arkansas • Little Rock, Arkansas + 18 more
- Conditions
- Gram-positive Bacterial Infections
- Interventions
- Oritavancin
- Drug
- Lead sponsor
- Melinta Therapeutics, LLC
- Industry
- Eligibility
- Up to 18 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2025
- U.S. locations
- 8
- States / cities
- Little Rock, Arkansas • Orange, California • San Diego, California + 5 more
- Conditions
- Meningococcal Disease
- Interventions
- Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine
- Biological
- Lead sponsor
- Novartis Vaccines
- Industry
- Eligibility
- 7 Years to 15 Years
- Enrollment
- 465 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 15
- States / cities
- Bentonville, Arkansas • Little Rock, Arkansas • Downey, California + 10 more
- Conditions
- Bacterial Infection, Anti-infective Agents, Breast Implantation
- Interventions
- Cefadroxil discontinued early, Cefadroxil until drain removal
- Drug
- Lead sponsor
- Stony Brook University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 132 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Stony Brook, New York